HER2 Support Group Forums - View Single Post - Aragon initiates dosing in ARN-509 Phase 1/2 clinical trial for castration-resistant

News · 08-09-2010, 06:31 AM

Aragon Pharmaceuticals today announced the dosing of the first patient in a Phase 1/2 clinical trial of the company's lead compound, ARN-509, in patients with castration-resistant prostate cancer (CRPC).

More...

08-09-2010, 06:31 AM	#1
News Senior Member Join Date: Oct 2007 Posts: 18,975	Aragon initiates dosing in ARN-509 Phase 1/2 clinical trial for castration-resistant Aragon Pharmaceuticals today announced the dosing of the first patient in a Phase 1/2 clinical trial of the company's lead compound, ARN-509, in patients with castration-resistant prostate cancer (CRPC). More...